The Blue Jays got the worst possible news on Wednesday. Jose Berrios underwent a full Tommy John surgery on his right elbow and will miss the rest of the 2026 season and most of 2027. The Toronto rotation just lost its workhorse.
Manager John Schneider broke the news. Toronto had hoped Berrios would need a smaller procedure to clean out a stress fracture and remove loose bodies. Once Dr. Keith Meister got into the elbow in Texas, he found a loose body attached to the ulnar collateral ligament. The full Tommy John procedure was the only fix.
“He’ll be down for 12 to 14 months,” Schneider said. That is the standard timeline for a starting pitcher coming back from Tommy John surgery, and it puts Berrios on track to maybe return for the second half of 2027 if everything goes perfectly. Pitchers his age do not always come back at the same level. He is 31.
The contract complicates this. Berrios signed a seven-year, $131 million extension before the 2022 season. Toronto still owes him $77 million across the remaining four years. Those are not buyout numbers. Those are dead money numbers if he cannot get back to anything close to his pre-injury form.
Berrios was the most reliable starter in the Blue Jays rotation last season. He made 31 appearances, threw 192 innings, and put up a 3.71 ERA. He landed on the IL late in the year with right elbow inflammation, the first IL trip of his big-league career. That little warning sign turned out to be the start of this collapse.
This wrecks Toronto’s already shaky rotation plans. Kevin Gausman is the new ace by default. Bowden Francis has been good. Chris Bassitt has been okay. After that the rotation drops off into Yariel Rodriguez and a rotating cast of bullpen pieces who are now being asked to start. The Blue Jays are 22-26 and clinging to relevance in the AL East.
The trade deadline math just changed dramatically. Toronto was supposed to be a buyer if the team hovered around .500. Now they probably need to be a seller. Bo Bichette is in his walk year. Vlad Jr. is two years from his. Both have made it clear they expect to test the market when their deals are up. Trading them at the deadline is the only way for this front office to come out of the next 24 months with anything to show for it.
The Berrios loss does not just hurt 2026. It hurts the long-term plan. Toronto was supposed to lean on his veteran presence and innings-eating capability through the next phase of the rebuild. Losing him for a year and a half forces the team to find another reliable starter from a market that does not have many available.
Tommy John surgery is also not what it was 15 years ago. Pitchers come back from it. The recovery is well understood. But the return rate to elite production is closer to 60 percent than 80 percent, and the rate of secondary injuries within three years of the surgery is higher than ever. Berrios is going to come back. The question is whether he comes back as the same pitcher.
The Blue Jays will get an insurance payment on the contract that helps but does not solve the problem. They will get a 60-day IL roster move that frees up a spot for a rotation piece. They will get a chance to evaluate young arms like Adam Macko and Ricky Tiedemann under pressure. None of that fixes the rotation in 2026.
This is the kind of injury that breaks seasons. Toronto’s was already in trouble. Now it is in real trouble. The 2027 plan starts now, whether the Blue Jays admit it or not.
A longtime sports reporter, Carlos Garcia has written about some of the biggest and most notable athletic events of the last 5 years. He has been credentialed to cover MLS, NBA and MLB games all over the United States. His work has been published on Fox Sports, Bleacher Report, AOL and the Washington Post.
